Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Adaptive Biotechnologies Corp (NASDAQ: ADPT) closed at $8.13 in the last session, up 1.50% from day before closing price of $8.01. In other words, the price has increased by $1.50 from its previous closing price. On the day, 2.22 million shares were traded. ADPT stock price reached its highest trading level at $8.225 during the session, while it also had its lowest trading level at $7.6501.
Ratios:
We take a closer look at ADPT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.38 and its Current Ratio is at 3.52. In the meantime, Its Debt-to-Equity ratio is 1.00 whereas as Long-Term Debt/Eq ratio is at 0.96.
On January 05, 2023, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $15.
Piper Sandler Upgraded its Neutral to Overweight on December 21, 2022, whereas the target price for the stock was revised from $7.50 to $14.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 18 ’24 when PISKEL KYLE sold 248 shares for $4.98 per share. The transaction valued at 1,235 led to the insider holds 154,330 shares of the business.
Taylor Stacy L sold 26,922 shares of ADPT for $121,079 on Aug 22 ’24. The SVP and General Counsel now owns 139,365 shares after completing the transaction at $4.50 per share. On Aug 22 ’24, another insider, STACY L TAYLOR, who serves as the Officer of the company, bought 26,922 shares for $4.50 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADPT now has a Market Capitalization of 1199817344 and an Enterprise Value of 1180818176. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.77 while its Price-to-Book (P/B) ratio in mrq is 5.36. Its current Enterprise Value per Revenue stands at 6.661 whereas that against EBITDA is -8.036.
Stock Price History:
The Beta on a monthly basis for ADPT is 1.51, which has changed by 1.027848 over the last 52 weeks, in comparison to a change of 0.24440956 over the same period for the S&P500. Over the past 52 weeks, ADPT has reached a high of $8.33, while it has fallen to a 52-week low of $2.28. The 50-Day Moving Average of the stock is 30.89%, while the 200-Day Moving Average is calculated to be 77.64%.
Shares Statistics:
According to the various share statistics, ADPT traded on average about 1.34M shares per day over the past 3-months and 1827780 shares per day over the past 10 days. A total of 147.56M shares are outstanding, with a floating share count of 142.73M. Insiders hold about 3.28% of the company’s shares, while institutions hold 92.28% stake in the company. Shares short for ADPT as of 1735603200 were 9189671 with a Short Ratio of 6.86, compared to 1732838400 on 9579850. Therefore, it implies a Short% of Shares Outstanding of 9189671 and a Short% of Float of 8.0.
Earnings Estimates
As of right now, 5.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.25 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$1.09 and -$1.11 for the fiscal current year, implying an average EPS of -$1.11. EPS for the following year is -$0.86, with 5.0 analysts recommending between -$0.8 and -$0.94.
Revenue Estimates
According to 7 analysts, the current quarter’s revenue is expected to be $46.15M. It ranges from a high estimate of $48M to a low estimate of $43M. As of the current estimate, Adaptive Biotechnologies Corp’s year-ago sales were $45.78MFor the next quarter, 7 analysts are estimating revenue of $46.49M. There is a high estimate of $49.34M for the next quarter, whereas the lowest estimate is $42.49M.
A total of 8 analysts have provided revenue estimates for ADPT’s current fiscal year. The highest revenue estimate was $179.63M, while the lowest revenue estimate was $174M, resulting in an average revenue estimate of $177.66M. In the same quarter a year ago, actual revenue was $170.28MBased on 8 analysts’ estimates, the company’s revenue will be $210.99M in the next fiscal year. The high estimate is $220.9M and the low estimate is $204M.
